Long-term Use and Safety of JAK Inhibitors and Evaluating Efficacy Outcomes in Atopic Dermatitis

Christopher G. Bunick, MD, PhD, discusses what can be done to improve the standard of care for atopic dermatitis (AD).

Christopher G. Bunick, MD, PhD, provides an overview of clinical trial outcomes in atopic dermatitis (AD).

A dermatology expert discusses how the standard of care EASI scores have been improving with newer atopic dermatitis (AD) therapies.

A dermatology expert discusses how numerical rating scale (NRS) is used in atopic dermatitis (AD) clinical trials.

Christopher G. Bunick, MD, PhD, discusses underutilized efficacy outcomes in atopic dermatitis (AD) clinical trials.

A dermatology expert provides an overview of the results of the meta-analysis data from the RAD 2023 atopic dermatitis (AD) trial.

Christopher G. Bunick, MD, PhD, shares their clinical approach for switching therapies for atopic dermatitis (AD) treatment.

Andrew Blauvelt, MD, provides an overview of different treatment options that are available for patients with moderate to severe atopic dermatitis (AD).

Andrew Blauvelt, MD, provides an overview of the significance of JAK/Stat pathway inhibition in targeting the pathophysiology of atopic dermatology (AD).

An expert discusses treatment selection for atopic dermatitis (AD) based on short and long-term data.

A dermatology expert discusses taking a nuanced approach to interpreting the boxed warnings for JAK inhibitor for atopic dermatitis (AD) treatment.

Andrew Blauvelt, MD, discusses upadacitinib for the treatment of atopic dermatitis (AD).

Andrew Blauvelt, MD, discusses switching therapies for atopic dermatitis (AD) treatment.